Dataset related to article "The Complementary Role of PSMA Expression and [18F]FDG PET/CT in Predicting Thyroid Cancer Outcome - from Black and White to Shades of Gray, in the Era of Precision Oncology"
Authors/Creators
- 1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy AND Nuclear Medicine, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy
- 2. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 3. IRCCS Humanitas Research Hospital, via Manzoni 56,20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele – Milan, Italy
- 4. IRCCS Humanitas Research Hospital, via Manzoni 56, 20072 Rozzano (Mi) - Italy
Description
This record contains data related to article "The Complementary Role of PSMA Expression and [18F]FDG PET/CT in Predicting Thyroid Cancer Outcome - from Black and White to Shades of Gray, in the Era of Precision Oncology"
Abstract
Background The value of Prostate Specific Membrane Antigen (PSMA) in thyroid carcinoma (TC) is still unknown. We
aimed to test the potential complementary role of PSMA expression and 2-[18F]fluoro-2-deoxy-D-glucose ([
18F]FDG)
uptake on PET/CT as biomarkers for TC outcome prediction.
Materials and methods From a retrospective cohort of TC patients we selected those fulfilling the following inclusion/
exclusion criteria: thyroidectomy in our Institution, available primary tumor tissue PSMA immunostaining, [
18F]
FDG PET/CT and follow-up data. PSMA staining was visually assessed. PET/CT was considered positive in case of [
18F]
FDG uptake higher than the background at the site of TC confirmed by cyto-/histology, and/or follow-up. Disease
recurrence, radioiodine refractoriness (RAI-R) and status at last follow-up (LFU) were used as outcome endpoints.
Results We included 23 subjects. Disease recurrence occurred in 18 patients (median time 11 months, range 1–40);
among these 12/18 developed RAI-R (median time 28 months, range 2–221), and 13/18 had evidence of disease at
LFU. PSMA expression was negative in 6/23 cases. PET/CT was negative in 11/23 patients (7/11 experienced recurrence).
PET/CT was positive in 9/12 patients showing RAI-R and 10/13 cases with evidence of disease at LFU. All
patients with positive PET/CT had a positive PSMA immunostaining. Six out of 11 patients with negative PET/CT were
positive at immunostaining, showing lower PSMA expression (median score of 30%, range 0–80%) than patients with
positive PET/CT. The TC samples without PSMA expression belonged to patients who resulted negative also at PET/CT
(3 experienced recurrence, 2 were RAI-R, and 1 had disease at LFU). Four out of 11 patients who resulted negative at
PET/CT exhibited very high PSMA expression (≥ 70%) and although 3 of them experienced recurrence, none resulted
RAI-R, and only 1 had persistent disease at LFU.
Conclusions Primary tumor PSMA expression and [
18F]FDG uptake seem to play a complementary prognostic role in
TC. The majority of patients who expressed PSMA recurred. In the intermediate ATA risk class, patients with negative
PSMA immunostaining recurred less than patients expressing PSMA. Additionally, although patients with a negative
Files
Restricted
The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/7808016">Log in</a> to check if you have access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
This set of data is accessible only upon request because it includes sensitive data.
Please write your request to biblioteca@humanitas.it
You are currently not logged in. Do you have an account? Log in here
Additional details
Related works
- Is supplement to
- Journal article: 10.1186/s13550-023-01004-2 (DOI)
- Journal article: 37261582 (PMID)